FindTrial
Sign In

Role of SGLT2I in Patients With Myocardial Infarction

Role of SGLT2I in Diabetic Patients With Myocardial Infarction

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06245980
Enrollment
1200
Registered
2024-02-07
Start date
2018-01-01
Completion date
2024-03-31
Last updated
2024-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Myocardial Infarction

Brief summary

Role of sglt2I in diabetic patients with myocardial infarction

Interventions

DRUGSGLT2 inhibitor

According to whether SGLT2i was used

Sponsors

Dongying Zhang
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Acute myocardial infarction patients 2. Type 2 diabetics.

Exclusion criteria

1. Patients undergoing coronary artery bypass grafting (CABG). 2. Severe valvular heart disease. 3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins. 4. Previously used SGLT2i. 5. Severe hepatic and renal insufficiency.

Design outcomes

Primary

MeasureTime frameDescription
MACE24monthscardiovascular death and heart failure and myocardial infarction
Heart failure readmission24monthsHeart failure readmission

Secondary

MeasureTime frameDescription
Recurrent myocardial infarction24monthsRecurrent myocardial infarction
cardiovascular death24monthscardiovascular death

Countries

China

Contacts

Primary Contactxuesong wen
1979272415@qq.com+8618702384027

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026